Prognostic impact of matrix metalloproteinases 2,9, and 11 in stromal cells stage I non-small cell lung cancer;Prognostický význam matrix metaloproteáz 2,9 a 11 ve stromálních buňkách I. stadia nemalobuně čného karcinomu plic

Casopis Lekaru Ceskych

Volumn 146, Issue 1, 2007, Pages 45-47

  Dráč, Pert ^a,d   Klein, J ^a   Tichy T ^c   Kolek, V ^b   Skarda J ^c  

^a I chirurgicka klinika FN   (Czech Republic)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d Ústav Patologie LF UP ^*  (Czech Republic)

Author keywords

Matrix metalloproteinases; Non small cell lung cancer; Stromal cells

Indexed keywords

GELATINASE A; GELATINASE B; STROMELYSIN 3;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; LUNG NON SMALL CELL CANCER; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL; TUMOR CELL;

EID: 33846286092     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Čapov, I., Wechsler, J., Jedlička, V. et al.: Kritéria onkologické operability u nemalobuněč né formy plicní rakoviny. Klinická onkologie, 2003, 16, s. 49-53.
2. Crawford, H. C., Matrisian, L. M.: Tumour and stromal expression of matrix metalloproteinases and their role in tumor progression. Invas. Metast., 1994-1995, 14, s. 234-235.
3. Egeblad, M., Werb, Z.: New functions for the matrix metalloproneinases in cancer progression. Nat. Rev. Cancer., 2002, 2, s. 161-174.
4. Freije, J. M., Balbin, M., Pendas, A. et al.: Matrix metalloproteinases and tumor progression. Adv. Exp. Biol., 2003, 532, s. 91-107.
5. Hojilla, C. V., Mohammed, F. F., Khokha, R.: Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br. J. Cancer., 2003, 89, s. 1817-1822.
6. Perez-Ramos, J., de Lourdes Segura-Valdez, M., Vanda, B. et al.: Matrix metalloproteinases 2,9, and 13, and tissue inhibitors of metalloproteinases 1 and 2 in experimental lung silicosis. Am. J. Respir. Crit. Care Med., 1999, 160, s. 1274-1282.
7. Woessner, J. F., Nagase, H.: Matrix metalloproteinases and TIMPs. New York, Oxford University Press, 2000.
8. Liu, L. T., Chang, H. C., Chiang, L. C., Hung, W. C.: Induction of RECK by nonsteroidal anti-inflammatory drugs in lung cancer cells. Oncogene, 2002, 54, s. 8347-8350.
9. Yamamoto, A., Yano, S., Shiraga, M. et al.: A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel supresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. Int. J. Cancer., 2003, 103, s. 822-828.
10. Lockhart, A. C., Braun, R. D., Yu, D. et al.: Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 2003, 9, s. 586-593.
11. Su, J. M., Wei, Y. Q., Tian, L. et al.: Active immunogene therapy of cancer with vaccine on the basis of chicken homologous Matrix metalloproteinase-2. Cancer Res., 2003, 63, s. 600-607.
12. Bolon, I., Devouassoux, M., Robert, C. et al.: Expression of urokinase-type plaminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. Am. J. Pathol., 1997, 150, s. 1619-1629.
13. O'Byrne, K. J., Cox, G., Swinson, D. et al.: Towards a biological staging model for operable non-small cell lung cancer. Lung Cancer, 2001, 34, s. 83-89.
14. Klein, J., Král, V., Tichý, T. et al.: Markers of tumor invasion as predictors of survival after resection of NSCLC. Int. J. Cancer, 2002, 99, s. 419-422.
15. Delebecq T. J., Porte, H., Zerimech, F. et al.: Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. Clin. Cancer Res., 2000, 6, s. 1086-1092.
16. Collier, I. E., Wilhelm, S. M., Eisen, A. Z. et al.: H-ras oncogene-transformed bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J. biol. Chem., 1988, 263, s. 6579-6587.
17. Galateau-Salle, F. B., Luna, R. E., Horiba, K. et al.: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Human pathology, 2000, 31, s. 296-304.
18. Nawrocki, B., Polette, M., Marchand, V. et al.: Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int. J. Cancer, 1997, 72, s. 556-564.
19. Sienel, W., Hellers, J., Morresi-Hauf, A. et al.: Prognostic impact of matrix metalloproteinase-9 in operable non-small-cell lung cancer. Int. J. Cancer, 2003, 20, s. 647-651.